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ABSTRACT
This study used pharmacokinetic–pharmacodynamic (PK–PD) modelling and MICs of 15 antimicrobial
agents, derived from testing a large international culture collection, to assist in the development of
interpretative criteria, i.e., breakpoints, for Neisseria meningitidis. PK parameters, protein binding,
percentage penetration into cerebrospinal fluid (CSF), and the variability of these values, were extracted
from the published literature for the 15 agents. PK–PD parameters have not been developed specifically
for N. meningitidis in animal or human studies. Thus, it was necessary to invoke PK–PD targets from
other organisms that cause infections at similar sites. The PK–PD targets utilised were: time above the
MIC for at least 50% of the dosing interval for all b-lactams, chloramphenicol, sulphafurazole and
trimethoprim–sulphamethoxazole; an AUC ⁄MIC ratio of ‡25 for the tetracyclines and macrolides; and
an AUC ⁄MIC ratio of ‡125 for the fluoroquinolones. A 10 000-subject Monte Carlo simulation was
designed with the usual dosing regimens of each antimicrobial agent at MIC values of 0.03–64 mg ⁄L in
both serum and CSF. The PK–PD breakpoint was defined as the MIC at which the calculated target
attainment was ‡95%. Using these assumptions, the proposed PK–PD breakpoints were: azithromycin,
0.125 mg ⁄L; doxycycline, 0.25 mg ⁄L; cefotaxime, ciprofloxacin and levofloxacin, 0.5 mg ⁄L; penicillin G,
meropenem, rifampicin, tetracycline and minocycline, 1 mg ⁄L; chloramphenicol and sulphafurazole,
2 mg ⁄L; and ampicillin, ceftriaxone and trimethoprim–sulphamethoxazole, 4 mg ⁄L. Proposed PK–PD
breakpoints applicable to CSF were: penicillin and cefotaxime, 0.06 mg ⁄L; rifampicin, 0.125 mg ⁄L;
ceftriaxone, meropenem and trimethoprim–sulphamethoxazole, 0.25 mg ⁄L; ampicillin, 0.5 mg ⁄L; and
chloramphenicol, 1 mg ⁄L.
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INTRODUCTION
The CLSI (formerly NCCLS) has recently defined
antimicrobial susceptibility testing conditions for
Neisseria meningitidis for the first time [1]. The
previous absence of specific interpretative criteria
for various antimicrobial agents when tested
against N. meningitidis has hindered recognition
of emerging antimicrobial resistance in an organ-
ism of major public health significance. Although
relatively uncommon in developed countries,
meningococcal infections are associated with a
mortality rate of c. 10%, and c. 13% of survivors
will have long-term sequelae, including hearing
loss, neurological disability and loss of limbs [2,3].
The disease is highly communicable, but current
vaccines have limitations, including an absence
of coverage of serogroup B and ineffectiveness
in young infants [4,5]. Given the morbidity
and mortality associated with meningococcal
Corresponding author and reprint requests: D. S. Burgess,
Clinical Pharmacy Programs-MSC 6220, The University of
Texas Health Science Center, 7703 Floyd Curl Drive, San
Antonio, TX, 78229-3900, USA
E-mail: Burgessd@uthscsa.edu
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
infections, and the absence of vaccines with a
broad coverage, it is important that antimicrobial
susceptibility criteria, i.e., breakpoints, be devel-
oped to assess emerging trends in resistance that
would impact on therapy for invasive infections
or prophylaxis for case contacts.
The CLSI publishes annual standards for sus-
ceptibility testing and interpretation of results.
The interpretative susceptibility criteria are the
MICs or disk-diffusion zone diameters that pro-
vide an indication of likely clinical success when a
specific antimicrobial agent is used to treat an
infection. The CLSI has traditionally used a
combination of MIC distributions of wild-type
strains, MICs of strains with known resistance
mechanisms, basic pharmacokinetic–pharmaco-
dynamic (PK–PD) data and clinical trial results
to establish breakpoints. Recently, the CLSI has
added more extensive PK–PD modelling to these
criteria as an additional tool for breakpoint
determinations. PK–PD models utilise mathemat-
ics to simultaneously integrate the activity of
antimicrobial agents with bacterial and patient
characteristics to enable investigators to predict
likely antimicrobial efficacy, based on previously
established PK–PD relationships.
The present study used PK–PD modelling to
assist in the initial establishment of interpretative
susceptibility criteria for N. meningitidis. Com-
bined with a previous study that described
in-vitro susceptibility testing and the molecular
characterisation of relevant resistance mecha-
nisms [6], and some very limited clinical therapy
data, the results of the present study contributed
to the development of the new CLSI breakpoints
for N. meningitidis [7].
MATERIALS AND METHODS
Meningococcal isolates
The general characteristics of the isolate collection, suscepti-
bility testing methods and methods for the molecular charac-
terisation of resistance mechanisms have been described
previously [6]. In brief, 441 N. meningitidis isolates were
obtained from the US CDC, numerous US state health
departments and international laboratories. All testing was
conducted in accordance with CLSI recommendations at the
University of Texas Health Science Center at San Antonio, TX,
USA.
Antimicrobial agents
Fifteen antimicrobial agents were chosen, based on their
recommended use for therapy or prophylaxis of meningococ-
cal infections. PK–PD parameters, protein binding, and the
variability of these measurements, were obtained from the
published literature for ampicillin, azithromycin, cefotaxime,
ceftriaxone, chloramphenicol, ciprofloxacin, doxycycline, lev-
ofloxacin, meropenem, minocycline, penicillin G, rifampicin,
sulphafurazole, tetracycline and trimethoprim–sulphameth-
oxazole (Table 1) [8–21]. Data concerning penetration into the
cerebrospinal fluid (CSF) were also obtained from the litera-
ture [22–24]. PK studies were identified using an OVID search
engine to query the Medline database. A Medline search was
performed individually for each antimicrobial agent by com-
bining the exploded MeSH heading ‘pharmacokinetics’ with
each antimicrobial agent’s generic name, and by limiting the
results to studies of healthy individuals published in English
between 1970 and 2003. In addition, suitable studies were
identified that evaluated clinically relevant dosing regimens
and provided the means and standard deviations for PK
parameters of interest. These values were available, with few
exceptions, only for adults.
Table 1. Pharmacokinetic parameters for antimicrobial agents included in the study
Antimicrobial agent Vd (L ⁄ kg) t1 ⁄ 2 (h) AUC (mg h ⁄L) fu (%) %CSFa
Ampicillin 2 g every 6 h [9] 18.9 ± 2.6 1.09 ± 0.16 – 75–85 11–18
Azithromycin 500 mg every 24 hb – – 8.03 ± 0.86 75–85 –
Cefotaxime 2 g every 8 h [10] 0.23 ± 0.07 1.18 ± 0.34 – 75–85 8–16
Ceftriaxone 2 g every 24 h [11] 0.12 ± 0.02 7.50 ± 0.60 – 3–10 8–16
Chloramphenicol 1 g every 6 h [13] 0.81 ± 0.18 3.20 ± 1.02 – 45–66 45–89
Ciprofloxacin 400 mg every 12 h [19] – – 24.4 ± 3.00 65–75 26–37
Doxycycline 100 mg every 12 h [20] 50.5 ± 8.7 16.20 ± 2.60 – 10–20 –
Levofloxacin 500 mg every 24 h [21] – – 47.70 ± 7.60 65–75 30–50
Meropenem 1 g every 8 h [12] 18.60 ± 3.00 1.07 ± 0.11 – 90–99 10–30
Minocycline 100 mg every 12 h [15] 9.49 ± 1.20 17.90 ± 4.10 – 30–40 –
Penicillin G 3 MU every 4 h [8] 23.5 ± 11.3 0.53 ± 0.09 – 35–45 5–10
Rifampicin 600 mg every 24 h [18] 0.51 ± 0.10 3.41 ± 0.86 – 50–60 7–56
Sulphafurazole 1 g every 6 h [16] 10.90 ± 2.00 6.80 ± 0.50 – 5–15 –
Tetracycline 500 mg every 6 h [14] 1.54 ± 0.23 10.55 ± 1.49 – 30–40 –
TMP ⁄ SMX 360 ⁄ 80 mg every 12 h [17] 1.78 ± 0.43 14.60 ± 2.60 – 50–60 10–30
Vd, volume of distribution; t1 ⁄ 2, half-life; AUC, area under the concentration–time curve; fu, unbound fraction; %CSF, percentage penetration into the cerebrospinal fluid;
TMP ⁄ SMX, trimethoprim–sulphamethoxazole.
a%CSF was obtained from the literature [22–24].
bInformation for azithromycin was obtained from the manufacturer’s package labelling (Zithromax IV; Pfizer Labs, Division of Pfizer Inc., New York, NY, USA).
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PK–PD models
Crystal Ball (Decisioneering, Inc., Denver, CO, USA) was used
to perform a 10 000-subject Monte Carlo simulation in both the
serum and CSF for each antimicrobial agent at MICs from 0.03
to 64 mg ⁄L. The models permitted variation in protein
binding, PK parameters and percentage CSF penetration.
Although PK–PD models enable regimen-specific breakpoints
to be established, the CLSI has generally advocated only a
single set of breakpoints for each antimicrobial agent–organ-
ism pair. For this reason, only the most common antimicrobial
regimens were modelled. The percentage time above the MIC
was calculated according to an established PK–PD equation
[25]. The subject weight was fixed at 70 kg for all simulations,
and the free percentage time above the MIC was obtained by
multiplying the dose by the unbound fraction. Similarly, the
free AUC ⁄MIC was calculated by multiplying the AUC ⁄MIC
ratio by the unbound fraction. CSF models were created by
multiplying each respective equation by the percentage CSF
penetration. Basic PK studies have not been performed
specifically for N. meningitidis in animals or humans. Thus,
for the purpose of this study, well-recognised PK–PD concepts
that have been developed for other organisms causing serious
systemic infections, including meningitis, were used. For
b-lactams, chloramphenicol, sulphafurazole, trimethoprim and
trimethoprim–sulphamethoxazole, the PK–PD target chosen
was a percentage time above the MIC of ‡50% [23,24,26]. In
contrast, the PK–PD target chosen was an AUC ⁄MIC ratio of
‡25 for the tetracyclines and macrolides, and of ‡125 for the
fluoroquinolones [23,23,26]. The susceptible PK–PD breakpoint
was defined as the MIC at which target attainment was ‡95%.
The susceptibility of meningococcal isolates was defined on
the basis of applying the PK–PD breakpoints. Finally, for
azithromycin, the susceptible percentage was based on MICs
determined with incubation in ambient air, rather than in a
CO2 atmosphere.
RESULTS
Activities of antimicrobial agents
In-vitro activities of the 15 agents have been
described previously [6]. A brief summary of
MICs is shown in Table 2. In general, MICs were
low (MIC50 ⁄ 90, £1 ⁄ £2 mg ⁄L) and MIC ranges were
narrow (MIC50, £0.0015–1 and MIC90, £0.0015–
2 mg ⁄L), except for sulphafurazole (MIC50 ⁄ 90,
8 ⁄>64 mg ⁄L). Third-generation cephalosporins,
fluoroquinolones and carbapenems had the low-
est MICs.
PK–PD breakpoints
Detailed data showing the probabilities of target
attainment and the MIC distributions of each
agent for N. meningitidis, based upon the Monte
Carlo simulations, are shown in Fig. S1 (see
Supplementary material). For drugs known to
achieve good CSF penetration, both serum and
CSF probabilities are presented. For third-genera-
tion cephalosporins, fluoroquinolones and carb-
apenems, the susceptible PK–PD breakpoint (the
MIC at which the probability of target attainment
was ‡95%) was well above the observed MIC
distribution. However, the susceptible PK–PD
breakpoint bisected the MIC distribution for the
penicillins, tetracyclines, macrolides, rifampicin,
chloramphenicol, sulphafurazole and trimetho-
prim–sulphamethoxazole.
Table 3 summarises the suggested PK–PD
breakpoints, based on both the serum and CSF
PK parameters. For serum-based calculations,
susceptible PK–PD breakpoints of most anti-
microbial agents were 1 or 2 mg ⁄L. However,
azithromycin (0.125 mg ⁄L), doxycycline (0.25
mg ⁄L), cefotaxime (0.5 mg ⁄L) and ciprofloxacin
(0.5 mg ⁄L) had initial breakpoints <1 mg ⁄L, while




isolates MIC50 MIC90 MIC range
Ampicillin 441 0.06 0.25 0.015–1
Azithromycin (in air) 100 0.06 0.12 £0.03–0.25
Cefotaxime 441 0.003 0.007 £0.0015–0.03
Ceftriaxone 441 £0.0015 £0.0015 £0.0015–0.003
Chloramphenicol 441 1 2 0.5–16
Ciprofloxacin 441 0.003 0.003 £0.0015–0.06
Doxycycline 124 0.5 1 0.12–2
Levofloxacin 124 0.007 0.007 0.007–0.06
Meropenem 441 0.007 0.015 £0.0015–0.06
Minocycline 441 0.12 0.25 £0.06–0.5
Penicillin 441 0.06 0.12 £0.007–1
Rifampicin 441 0.03 0.12 £0.007 to >256
Sulphafurazole 441 8 >64 £0.25 to >64
Tetracycline 441 0.5 1 0.12–16
Trimethoprim–
sulphamethoxazole
441 0.5 2 £0.03–8
aIsolates were obtained from 20 states in the USA and 14 countries. Isolates
represent serogroups A, B, C, W-135, X, Y and Z from 1917–2004.
Table 3. Susceptible pharmacokinetic–pharmacodynamic
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ampicillin (4 mg ⁄L), ceftriaxone (4 mg ⁄L) and
trimethoprim–sulphamethoxazole (4 mg ⁄L) had
the highest tentative breakpoints based on serum
concentrations. In general, the suggested CSF PK–
PD breakpoints were eight- to 16-fold lower than
those for serum.
Antimicrobial susceptibility based on PK–PD
breakpoints
Table 4 summarises N. meningitidis susceptibility
based on the suggested PK–PD breakpoints.
Based on serum concentrations, >90% of N. men-
ingitidis isolates were susceptible to all agents,
except sulphafurazole (42%) and doxycycline
(28%). Among antimicrobial agents that pene-
trated the CSF, >90% of N. meningitidis isolates
were susceptible to ampicillin, cefotaxime, ceftri-
axone, meropenem and rifampicin. The suscept-
ible percentage was lower for penicillin G (83%),
chloramphenicol (62%) and trimethoprim–sul-
phamethoxazole (46%).
DISCUSSION
Clinically relevant susceptibility interpretative
criteria are critical for N. meningitidis because
invasive meningococcal infections are associated
with a high degree of morbidity and mortality.
While breakpoints can be developed readily from
microbiological data alone, the clinical utility of
breakpoints for N. meningitidis depends on
in-vivo factors such as CSF penetration and local
activity. Clinical studies in humans provide the
best means to account for all of these factors;
however, meningococcal clinical studies are few
in number and consist primarily of single case
reports and small case series [27–33]. In the
absence of optimal clinical data, PK–PD studies
represent a way to address these clinical ques-
tions. While not perfect, PK–PD studies enhance
the breakpoint development process by predict-
ing clinical response, based on the integration of
microbiological and PK factors.
The present study demonstrates the utility of
PK–PD modelling for the development of break-
points for N. meningitidis. Since the PK–PD mod-
els described in this study are independent of
MIC distributions, these models are applicable for
all systemic and CSF infections so long as the PK
parameters and PK–PD targets remain constant
(e.g., AUC ⁄MIC ‡125 for fluoroquinolones). As
data from animal models or human infections are
not available specifically for meningococci, the
present study used PK–PD targets that have been
established previously. The absence of back-
ground PD data for meningococci represents a
potential shortcoming of this study. Despite this,
the concepts used in this study represent a
rational starting point for the establishment of
PK–PD breakpoints for both systemic and CSF
infections, regardless of the infecting pathogen.
The need for both systemic and CSF break-
points depends on the pathogen’s propensity to
cause meningitis. Among patients infected with
N. meningitidis, c. 50% will develop meningitis
[34]. In contrast, <5% of Streptococcus pneumoniae
infections spread to the central nervous system
[35]. While the present study proposes both
systemic and CSF PK–PD breakpoints for N. men-
ingitidis, the CLSI recognised that N. meningitidis
frequently causes meningitis, and established
only a single set of breakpoints. In contrast, the
CLSI endorsed both systemic and CSF break-
points for S. pneumoniae [7].
In addition to the proposal of PK–PD break-
points for N. meningitidis, the present study pro-
duced several findings worthy of further
discussion. First, the PK–PD breakpoints for
ampicillin vs. penicillin G were four-fold higher
in serum and eight-fold higher in CSF. While
penicillin G was more potent, based on the MIC90
(0.12 vs. 0.25 mg ⁄L), ampicillin has more favour-
able pharmacokinetics, including a longer half-life
and a greater unbound serum fraction. The
favourable pharmacokinetics were able to
Table 4. Susceptibility of meningococcal isolates based on
the suggested pharmacokinetic–pharmacodynamic break-
points

















aThe percentage susceptible to azithromycin was based on MICs determined in
ambient air.
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overcome the decreased potency and resulted,
ultimately, in higher proposed PK–PD break-
points for ampicillin than for penicillin G. Second,
the proposed PK–PD breakpoint for doxycycline
(unlike minocycline) bisected the N. meningitidis
MIC distribution, resulting in a large portion of
isolates that would be reported as resistant. Such
a breakpoint would not be clinically useful.
Finally, the PK–PD models indicate that the CSF
breakpoint for ceftriaxone should be four-fold
higher than that for cefotaxime; however, the
CLSI selected a susceptible breakpoint of
0.12 mg ⁄L for both these agents, similar to exist-
ing breakpoints for S. pneumoniae [7].
While PK–PD models are helpful in establish-
ing breakpoints, it is important to remember that
these models are based on a number of assump-
tions. First, the basic justification for PK–PD
modelling is that previous studies have identified
correlations between PK–PD indices (i.e., AUC ⁄
MIC) and treatment outcomes. For N. meningitid-
is, there is no confirmation of the specific, rele-
vant, PK–PD targets; therefore, the PK–PD
assumptions used in this study were extrapolated
from PK–PD studies with other organisms. For
example, with the fluoroquinolones, it has been
shown that AUC ⁄MIC is the most appropriate
parameter for meningococci [23,24], while other
investigations have shown that the magnitude of
the PK–PD index for fluoroquinolones vs. Gram-
negative bacteria should be 100–125 [36,37]. Since
N. meningitidis is a Gram-negative bacterial spe-
cies, it was considered rational to use an
AUC ⁄MIC of 125 as the PK–PD target. For
tetracycline, trimethoprim–sulphamethoxazole
and chloramphenicol, the appropriate PK–PD
indexes have not been firmly established; thus,
PK–PD breakpoints based on both AUC ⁄MIC and
%T>MIC were evaluated, but no major differ-
ences were found (data not shown).
A second potential limitation is that these
PK–PD simulations were derived using MICs as
the microbiological data instead of minimum
bactericidal concentrations. However, since these
PK–PD models predict the likelihood of clinical
success in CSF, it may be worthwhile utilising
minimum bactericidal concentrations in a future
study. This alternative approach is unlikely to
change the results for bactericidal antimicrobial
agents, e.g., b-lactams, but may impact on the
probabilities of target attainment for bacteriostatic
antimicrobial agents [24]. With regard to the PK
data, the parameters used were from healthy
adults and pertained to values measured in serum
rather than CSF. This was necessary because of the
extremely limited PK data for children, for infec-
ted patients, and for CSF. For ethical reasons, PK
studies are not conducted in healthy children. In
contrast to volunteers, patients may have compro-
mised renal function, but since many antimicro-
bial agents are eliminated by renal excretion,
compromised renal function may result in in-
creased serum concentrations and a greater like-
lihood of achieving PK–PD targets. Consequently,
since CLSI breakpoints are used for patients with
both normal and compromised renal function, the
most conservative approach is to utilise PK
parameters from healthy volunteers. In support
of this practice, it has been demonstrated that the
probability of target attainment is similar whether
PK parameters are obtained from healthy volun-
teers or from patients [38].
Third, differences in CSF compared to serum
may impact on antibiotic activity. Thus, while the
CSF penetration data used in this study were
obtained primarily from studies among menin-
gitis patients rather than healthy adults, it is
known that CSF penetration varies substantially
among different studies [23,24]. This variation has
been attributed to study methodology, the
presence of inflamed meninges, and the adminis-
tration of concomitant medications (e.g., cortico-
steroids) [23,24]. To account for these issues, the
PK–PD models used in the present study were
designed to permit variation in CSF penetration
by modelling the penetration as a probability
distribution rather than a single value.
Finally, much debate exists as to the appropriate
value for target attainment (e.g., 90%, 95% or
100%). The most commonly used value has been
90%, but the present study utilised a more con-
servative value (i.e., 95%), mainly because of the
serious nature of meningococcal disease. How-
ever, the data shown in Fig. S1 (see Supplementary
material) allow possible PK–PD breakpoints to be
determined for any target attainment value
desired. Review of these targets suggests that the
breakpoints would be largely unchanged whether
targets of 90%, 95% or 100% were chosen.
Clinicians should recognise that this study
modelled only one dosing regimen for each
antimicrobial agent. The rationale behind the
dosing regimen selected was that the CLSI estab-
lishes breakpoints for the global community and
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that there is wide variation in the regimens used
in different countries. Higher doses can be used to
improve the PK–PD parameters and enhance the
probability of clinical success. For some agents,
the CLSI intermediate category represents a situ-
ation in which higher doses might prove effica-
cious, assuming that they can be administered
safely. In addition, paediatric dosing regimens
can be quite different for many antimicrobial
agents. It should be recognised that the microbio-
logical data (MIC distributions) and PK–PD mod-
elling results do not always suggest the same
breakpoints for an agent. It is therefore necessary
to consider all relevant data to establish the most
realistic and safest interpretative breakpoints for
each agent.
Findings from the present study, together with
previously described microbiological data, known
resistance mechanisms and limited clinical data,
were considered by the CLSI Antimicrobial Sus-
ceptibility Testing Sub-Committee during the
establishment of the final breakpoints that were
published in January 2005 [7]. The CLSI did not
approve the breakpoints for tetracycline or doxy-
cycline, as these agents are not used for treatment
of meningitis, and the doxycycline PK–PD model
did not suggest a clinically useful breakpoint.
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